FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982171370> ?p ?o ?g. }

• W2982171370 abstract "Abstract Background Exebacase, a lysin (cell wall hydrolase), is the first direct lytic agent to report Phase 2 study results in Staphylococcus aureus bacteremia including endocarditis. Among MRSA patients enrolled in this randomized, double-blind, placebo, controlled study, EXE used in addition to standard of care antibiotics (SoC), had 42.8% higher clinical responder rates (CRRs) compared SoC alone. We sought to determine whether these differences in CRRs translated into reductions in health resource utilization (HRU) in this population of critically ill, hospitalized patients. Methods The microbiological intent-to-treat population included 116 patients (71 EXE, 45 SoC) with documented S. aureus who received a single 2-hour infusion of blinded study drug dosed based on target attainment. The primary efficacy endpoint was CRR at Day 14. Diagnoses and clinical outcomes were determined by a blinded Adjudication Committee. HRU including length of stay (LOS), and 30-day hospital readmission rates (HRR) for all causes (AC) and for S. aureus (SA) were evaluated in MRSA patients who were alive at the time of discharge. Results The average patient was white, male and ~56 years old (67.8%). Twenty-seven EXe patients (38.0%) and 16 SoC patients (35.6%) had MRSA. All but 2 MRSA patients (1 EXE, 1 SoC) were enrolled in the United States. The Day 14 CRR were 70.4% for EXE and 60.0% for SoC groups (p=0.314) overall. In a prespecified analysis of MRSA patients, the CRR with EXE was 74.1% vs. 31.3% with SoC (P = 0.010). Among MRSA patients who received study drug, incidence of treatment emergent adverse events (TEAEs) was balanced between groups (24 (88.9%) in EXE and 15 (98.3%) in SoC) as were serious TEAEs (17(63.0%) in EXE, 12 (75%) in SoC). 1 EXE and 2 SoC US MRSA patients died in hospital. Among US MRSA patients discharged alive from the hospital, the median LOS after study drug was 6 vs. 10 days for EXE and SoC, respectively. Thirty-day AC HRR were 16% vs. 30.8%, for EXE vs. SoC, respectively, and 30-day SA HRR were 8% vs. 15.4%, respectively. Conclusions Exebacase used in addition to SoC was associated with a reduction in length of hospital stay and 30-day readmission rates for all causes and for S. aureus compared with SoC alone in patients being treated for MRSA bacteremia/endocarditis. Disclosures Cara Cassino, MD, ContraFect Corporation (Employee), Hemal Shah, PharmD, Boehringer Ingelheim (Consultant), ContraFect Corp (Consultant), DBV Technologies (Consultant), Mylan specialty (Consultant), Nabriva (Consultant), Joy Lipka-Diamond, MS, ContraFect Corporation (Consultant), Anita F. Das, PhD, Achaogen (Consultant), AntiobioTx (Consultant), Boston Pharmaceuticals (Consultant), Cempra (Consultant), ContraFect Corporation (Consultant), Iterum Therapeutics (Consultant), Nabriva (Consultant), Paratek (Consultant), Tetraphase (Consultant), UTILITY (Consultant), Wockhardt (Consultant)." @default.
• W2982171370 created "2019-11-01" @default.
• W2982171370 creator A5055756681 @default.
• W2982171370 creator A5069003618 @default.
• W2982171370 creator A5074779591 @default.
• W2982171370 creator A5089036530 @default.
• W2982171370 date "2019-10-01" @default.
• W2982171370 modified "2023-09-24" @default.
• W2982171370 title "LB3. Exebacase (EXE) Reduced Length of Stay and 30-Day Readmission Rates for US Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia Including Endocarditis Compared with Standard of Care Antibiotics (SoC) Alone in a Phase 2 Study" @default.
• W2982171370 doi "https://doi.org/10.1093/ofid/ofz415.2486" @default.
• W2982171370 hasPublicationYear "2019" @default.
• W2982171370 type Work @default.
• W2982171370 sameAs 2982171370 @default.
• W2982171370 citedByCount "0" @default.
• W2982171370 crossrefType "journal-article" @default.
• W2982171370 hasAuthorship W2982171370A5055756681 @default.
• W2982171370 hasAuthorship W2982171370A5069003618 @default.
• W2982171370 hasAuthorship W2982171370A5074779591 @default.
• W2982171370 hasAuthorship W2982171370A5089036530 @default.
• W2982171370 hasBestOaLocation W29821713701 @default.
• W2982171370 hasConcept C126322002 @default.
• W2982171370 hasConcept C2775872228 @default.
• W2982171370 hasConcept C2777052132 @default.
• W2982171370 hasConcept C2779443120 @default.
• W2982171370 hasConcept C2779489039 @default.
• W2982171370 hasConcept C501593827 @default.
• W2982171370 hasConcept C523546767 @default.
• W2982171370 hasConcept C54355233 @default.
• W2982171370 hasConcept C71924100 @default.
• W2982171370 hasConcept C86803240 @default.
• W2982171370 hasConcept C89423630 @default.
• W2982171370 hasConceptScore W2982171370C126322002 @default.
• W2982171370 hasConceptScore W2982171370C2775872228 @default.
• W2982171370 hasConceptScore W2982171370C2777052132 @default.
• W2982171370 hasConceptScore W2982171370C2779443120 @default.
• W2982171370 hasConceptScore W2982171370C2779489039 @default.
• W2982171370 hasConceptScore W2982171370C501593827 @default.
• W2982171370 hasConceptScore W2982171370C523546767 @default.
• W2982171370 hasConceptScore W2982171370C54355233 @default.
• W2982171370 hasConceptScore W2982171370C71924100 @default.
• W2982171370 hasConceptScore W2982171370C86803240 @default.
• W2982171370 hasConceptScore W2982171370C89423630 @default.
• W2982171370 hasLocation W29821713701 @default.
• W2982171370 hasLocation W29821713702 @default.
• W2982171370 hasOpenAccess W2982171370 @default.
• W2982171370 hasPrimaryLocation W29821713701 @default.
• W2982171370 hasRelatedWork W1979907199 @default.
• W2982171370 hasRelatedWork W1993578627 @default.
• W2982171370 hasRelatedWork W2017834980 @default.
• W2982171370 hasRelatedWork W2029699789 @default.
• W2982171370 hasRelatedWork W2116476574 @default.
• W2982171370 hasRelatedWork W2133902131 @default.
• W2982171370 hasRelatedWork W2144430392 @default.
• W2982171370 hasRelatedWork W2148440281 @default.
• W2982171370 hasRelatedWork W2521252357 @default.
• W2982171370 hasRelatedWork W2582120327 @default.
• W2982171370 hasRelatedWork W2788153224 @default.
• W2982171370 hasRelatedWork W2795358422 @default.
• W2982171370 hasRelatedWork W2803640917 @default.
• W2982171370 hasRelatedWork W2913656327 @default.
• W2982171370 hasRelatedWork W2981457542 @default.
• W2982171370 hasRelatedWork W3015983388 @default.
• W2982171370 hasRelatedWork W3154388069 @default.
• W2982171370 hasRelatedWork W3165513201 @default.
• W2982171370 hasRelatedWork W3184240786 @default.
• W2982171370 hasRelatedWork W3196399298 @default.
• W2982171370 isParatext "false" @default.
• W2982171370 isRetracted "false" @default.
• W2982171370 magId "2982171370" @default.
• W2982171370 workType "article" @default.